Covid-19 disease is a fatal viral respiratory disease caused by the SARS-CoV-2 virus. A wide range of clinical findings are seen, from asymptomatic to death. Therefore, it has been observed that empirical antibiotics were frequently used in hospitalizations due to secondary coinfection concerns. The data of 1186 hospitalized patients were analyzed retrospectively.4 groups(30 patients per group) consisting of a total of 120 patients were formed homogeneously. All patients who fulfilled the criteria(Covid PCR test positive, diagnosed with pneumonia, treated with Favipiravir, normal white blood cell and neutrophil, didn’t have bacterial infection, didn’t receive anti-inflammatory and steroid-derived drug) were included in the study. Data of all patients (age, gender, comorbidity, laboratory parameters, tomography reports, antibiotic and other drugs, need for intensive care and mortality) were evaluated retrospectively. The first group was levofloxacin, the second group combination of levofloxacin and ceftriaxone, the third group combination of levofloxacin and piperacillin tazobactam, and the fourth group combination of levofloxacin and meropenem. Combination treatment with levofloxacin ceftriaxone and levofloxacin meropenem is more effective in patients with comorbidities. Levofloxacin meropenem or levofloxacin ceftriaxone treatment in patients with interstitial pneumonia and levofloxacin or levofloxacin piperacillin tazobactam treatment in patients with lobular pneumonia is more effective.Levofloxacin ceftriaxone treatment is more effective on the decrease in CRP value,but there is no statistically significant difference between all treatments (p<0.05). Levofloxacin decreases hospital stay more than levofloxacin meropenem. Levofloxacin ceftriaxone decrease hospital stay more than levofloxacin piperacillin tazobactam and levofloxacin meropenem (p<0.05).There is no statistically significant difference between levofloxacin and levofloxacin ceftriaxone as length of hospital stay. Treatment cost sare have been found as levofloxacin